Stockscreener 앱 받기
0.51
8.93%
-0.05
시간 외 거래:
.50
-0.01
-1.96%
Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference - Investing News Network
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference - The Manila Times
Pasithea Therapeutics (KTTA) could find a support soon, here's why you should buy the stock now - MSN
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesEPS Consistency Score - newsline.com
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
KTTA Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises as Operational Efficiency ImprovesUpward Estimate Revision - newsline.com
PASITHEA THERAPEUTICS CORP (KTTA) Stock Chart - ChartMill
Why Is Pasithea Therapeutics Corp. (KTTAW) Stock Down Today? - Meyka
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis - Investing News Network
Pasithea receives orphan drug status for ALS treatment candidate - Investing.com
Pasithea receives orphan drug status for ALS treatment candidate By Investing.com - Investing.com South Africa
FDA grants rare-disease status to Pasithea ALS drug PAS-004 - Stock Titan
Pasithea Therapeutics (KTTA) Slips 3% as Shares Test Key Support Near $0.64Bollinger Squeeze - newsline.com
KTTA Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Surprise History - The Legal Advocate
Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans? - Sahm
Pasithea Therapeutics Corp. (KTTA) Q1 2026 Earnings: Significant EPS Beat Despite Zero RevenueHigh Interest Stocks - Newser
KTTA Q1 2026 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock SlipsPost-Announcement Reaction - thelegaladvocate.com
Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained - TipRanks
Pasithea Therapeutics (KTTA) Stalls at $0.78 — Breakout or Breakdown? 2026-05-18Collar Trade - newsline.com
Pasithea Therapeutics Corp.Common Stock (NQ: KTTA - The Chronicle-Journal
Pasithea Therapeutics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Pasithea Therapeutics Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Pasithea Therapeutics Corp. 1Q 2026: Net loss $(2.87M), EPS $(0.12) — 10-Q Summary - TradingView
Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pasithea Therapeutics (NASDAQ: KTTA) ramps PAS-004 R&D on $50M cash base - Stock Titan
Ameriprise (KTTA) reports 1.35M-share, 5.4% stake in Pasithea Therapeutics - Stock Titan
TradingKey - TradingKey
Pasithea Therapeutics appoints chief medical officer - MSN
KTTA Stock Price, Quote & Chart | PASITHEA THERAPEUTICS CORP (NASDAQ:KTTA) - ChartMill
Pasithea Therapeutics (KTTA) CEO awarded 1.76M stock options at $0.841 - Stock Titan
Pasithea (NASDAQ: KTTA) grants director 152,783 options at $0.841 strike - Stock Titan
Pasithea Therapeutics (KTTA) director receives 152,783 stock options grant - Stock Titan
Pasithea Therapeutics (KTTA) CFO receives 1.13M-share stock option grant - Stock Titan
[Form 4] Pasithea Therapeutics Corp. Insider Trading Activity - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) grants director Emer Leahy 152,783 options - Stock Titan
Pasithea (KTTA) director receives 152,783 stock options at $0.841 - Stock Titan
Pasithea Therapeutics (NASDAQ: KTTA) names Chief Medical Officer as reporting insider on Form 3 - Stock Titan
Pasithea Therapeutics Appoints Dr. Kartik Krishnan as Chief Medical Officer to Advance PAS-004 MEK Inhibitor for NF1 and Rare Diseases 12 - Minichart
8-K: Current report - Moomoo
Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives - TipRanks
New CMO and large option grants at Pasithea Therapeutics (NASDAQ: KTTA) - Stock Titan
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer - Investing News Network
Pasithea names Kartik Krishnan as chief medical officer By Investing.com - Investing.com South Africa
Pasithea Therapeutics Appoints Kartik Krishnan as Chief Medical Officer - citybiz
Pasithea names Kartik Krishnan as chief medical officer - Investing.com
1.27%
1.43%
자본화:
|
볼륨(24시간):